OTC · Biotechnology

Ceryvyn Therapeutics Limited (CKDXF) Stock

$0.01 +0.00% OTC: CKDXF Healthcare

Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies for the rare lung disease lymphangioleiomyomatosis (LAM). Its lead program, CYV-101, is a fusion protein designed to neutralize VEGF-C and VEGF-D, key signaling proteins involved in the disease.

Valuation

MetricValue
Price$0.01
Market Cap$13.68M
P/E Ratio0.06
P/B Ratio0.54
P/S Ratio-57.87
EPS (TTM)$0.17
52-Week High$0.44
52-Week Low$0.01
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-312.02%
ROA-285.96%
ROCE-140.10%
Gross Margin100.31%
Operating Margin-706200.00%
Net Margin0.00%
Debt/Equity-1.23
Current Ratio19.52

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-40.0M$-97.0M$-150.0M$-192.0M$-156.0M
Net Profit$-61.0M$-128.0M$-212.0M$-220.0M$-163.0M
EPS$-0.18$-0.34$-0.45$-0.35$-0.13
Op Margin-43098.0%-77201.3%-138912.0%-153885.4%-613622.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$184.0M$87.0M$148.0M$189.0M$57.0M
Total Liabilities$4.0M$18.0M$157.0M$265.0M$258.0M
Cash$157.0M$65.0M$134.0M$172.0M$48.0M
Borrowings$0$0$86.0M$142.0M$248.0M

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-61.0M$-98.0M$-179.0M$-161.0M$-159.0M
Investing Cash Flow$1.0M$0$0$0$0
Financing Cash Flow$-40.0M$0$-81.0M$85.0M$0
Net Cash Flow$76.0M$-74.0M$45.0M$83.0M$-124.0M
Free Cash Flow$-61.0M$-98.0M$-179.0M$-161.0M$-159.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.13
FCF Yield-768.23%
Quick Ratio19.52
Interest Coverage-0.97
Return 1Y-97.73%
Return 3Y-97.62%
Return 5Y—

Ownership

Insiders Held25.94%
Institutions Held8.38%
Institutions Float Held11.32%
Institutional HolderSharesReport Date
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund17,087,2932026-04-30
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund10,480,1762026-03-31
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap 4,172,6632026-04-30
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard Pacific Stock Index Fd.1,538,2682026-04-30
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard Total World Stock Index Fd.894,6972026-04-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Ceryvyn Therapeutics Limited

Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies for the rare lung disease lymphangioleiomyomatosis (LAM). Its lead program, CYV-101, is a fusion protein designed to neutralize VEGF-C and VEGF-D, key signaling proteins involved in the disease. The company was formerly known as Opthea Limited.

Ceryvyn Therapeutics Limited is headquartered in AU.

Ceryvyn Therapeutics Limited (CKDXF) stock trades at $0.01 with a market capitalization of $13.68M. The stock is valued at a price-to-earnings (P/E) ratio of 0.06, price-to-book of 0.54, price-to-sales of -57.87. Over the past 52 weeks the stock has ranged between $0.01 and $0.44, and currently trades 97.7% below its 52-week high.

On profitability, Ceryvyn Therapeutics Limited generates a return on equity (ROE) of -312.02%, return on capital employed of -140.10%, an operating margin of -706200.00%, a net profit margin of 0.00%.

Official website: www.ceryvyn.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides